Dynamic quotes: Off
|
Company Description (as filed with the SEC)
We develop, manufacture and sell proprietary biological testing technologies and products with applications throughout the life sciences and diagnostics industries. These industries depend on a broad range of tests, called bioassays, to perform diagnostic tests and conduct life science research. Our xMAP® (Multi-Analyte Profiling) technology, an open architecture, multiplexing technology, allows simultaneous analysis of up to 500 bioassays from a small sample volume, typically a single drop of fluid, by reading biological tests on the surface of microscopic polystyrene beads called microspheres. xMAP technology combines this miniaturized liquid array bioassay capability with small lasers, light emitting diodes (LEDs), digital signal processors, photo detectors, charge-coupled device imaging and proprietary software to create a system offering advantages in speed, precision, flexibility and cost. ... More ...
Analyst Info |
|
| Annual EPS Est: | $0.39 |
| Quarterly EPS Est: | 0.1 |
| PEG Ratio: | 3.08 |
|
Mean Recommendation: View Summary / View All |
2.5 |
Data is provided by Zacks Investment Research
